Tilray Brands Inc is a global leader in the cannabis industry, specializing in the cultivation, production, and distribution of a diverse range of cannabis products. The company operates across various segments, including medical and recreational cannabis, as well as hemp-derived wellness products. Tilray focuses on innovation and quality, offering a portfolio that encompasses various formats such as dried flower, oils, edibles, and beverages. In addition to its core cannabis business, Tilray is dedicated to advancing research, education, and consumer awareness within the rapidly evolving market, positioning itself as a key player in the development and expansion of cannabis-related offerings worldwide. Read More
In a paradoxical display of market confidence, shares of Tilray Brands (NASDAQ:TLRY) surged over 8% on Wednesday following the release of its fiscal third-quarter 2026 financial results. While the company delivered a "record" revenue performance of $206.7 million, outstripping analyst estimates of $201.3 million, it fell significantly
NEW YORK and LEAMINGTON, Ontario, March 25, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, today announced that the Company will release its financial results for the third fiscal quarter which ended February 28, 2026, before the financial markets open on Wednesday, April 1, 2026.
New restrictions approved by GOP legislators in Ohio have officially taken effect, altering the state’s voter-backed cannabis framework and introducing fresh criminal penalties. The measure, Senate Bill 56, also bans intoxicating hemp products, including drinks containing THC or CBD.
New restrictions approved by GOP legislators in Ohio have officially taken effect, altering the state’s voter-backed cannabis framework and introducing fresh criminal penalties. The measure, Senate Bill 56, also bans intoxicating hemp products, including drinks containing THC or CBD.
NEW YORK and SYDNEY, March 19, 2026 (GLOBE NEWSWIRE) -- Tilray Medical, a recognized global leader in medical cannabis and a division of Tilray Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY), today announced its largest portfolio expansion in Australia to date. The expanded medical cannabis offering reinforces Tilray Medical’s long-term commitment to the Australian market and supports increased patient access to regulated, clinically supported medical cannabis products.
NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”, “our”, “we” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis, and wellness industries, today announced that the Company has entered into an asset purchase agreement to acquire certain strategic assets of BrewDog in the United States, including its brewery, pub, and hotel in Columbus, Ohio, as well as the pubs in New Albany, Ohio, Cleveland, Ohio, and Las Vegas, Nevada. As one of the largest craft beer brands in Ohio, this acquisition aligns with Tilray’s regional jewel strategy.
Tilray slipped Thursday despite expanding its Germany healthcare partnership, as investors weighed the strategic move against broader market weakness and company-specific pressure.
DENSBORN, Germany, March 12, 2026 (GLOBE NEWSWIRE) -- Tilray Pharma, the pharmaceutical division of Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), has announced a strategic partnership with Tilray Medical, CC Pharma, 14U Pharma, and “gesund leben” cooperation, which is operated by Alliance Healthcare Deutschland. As one of Germany’s largest pharmacy networks, Alliance Healthcare Deutschland runs 27 logistics centers across the country and supplies more than 10,000 pharmacies daily. This comprehensive distribution network is recognized as a leading support system for independent pharmacies, providing essential services, marketing resources, and purchasing benefits. It plays a vital role in ensuring effective national pharmaceutical delivery.
A proposal aimed at restricting the THC amount in individual cannabis edibles will not move forward in Oregon this year after failing to clear the state House of Representatives.
A proposal aimed at restricting the THC amount in individual cannabis edibles will not move forward in Oregon this year after failing to clear the state House of Representatives.
